Skip to main content
. 2019 Feb;139(2):369–379. doi: 10.1016/j.jid.2018.08.020

Figure 3.

Figure 3

EGFR is degraded in the lysosome in KS cells through increased Cbl interactions. (a–c) Treatment of WT and KS cells with (a) proteasome inhibitor (MG132; 10 μmol/L, 24 hours) or lysosome inhibitors (b) leupeptin (100 nmol/L, 24 hours) (c) or concanamycin A (100 nmol/L, 24 hours) and analysis of EGFR levels by Western blotting. (d) Quantification of Western blots in a–c from four independent experiments. (e) Immunoprecipitation of EGFR from WT and KS cells after DMSO (–) or ConA treatment (100 nmol/L, 24 hours; +) and immunoblotting for c-Cbl. Blots beneath show c-Cbl levels in whole cell lysates. ConA, concanamycin A; EGFR, epidermal growth factor receptor; IP, immunoprecipitation; KS, Kindler syndrome; LP, leupeptin; WT, wild type.